Sukhatme Mayukh 4
4 · Roivant Sciences Ltd. · Filed Dec 19, 2025
Insider Transaction Report
Form 4
Sukhatme Mayukh
DirectorPresident & CIO
Transactions
- Exercise/Conversion
Common Shares
2025-12-17$12.68/sh+59,513$754,625→ 18,896,060 total - Sale
Common Shares
2025-12-17$23.09/sh−26,831$619,528→ 18,869,229 total - Other
Common Shares
2025-12-17$23.09/sh−32,682$754,627→ 18,836,547 total - Exercise/Conversion
Common Shares
2025-12-17−59,513→ 1,304,198 totalExercise: $12.68Exp: 2026-03-31→ Common Shares (59,513 underlying)
Footnotes (3)
- [F1]All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
- [F2]Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options.
- [F3]Award of stock options to purchase Common Shares that is fully vested.